Literature DB >> 20514442

Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line.

H K Dibra1, J E Brown, P Hooley, I D Nicholl.   

Abstract

Regular aspirin intake is associated with a reduction in the incidence of colorectal cancer. Aspirin has been shown to be cytotoxic to colorectal cancer cells in vitro. The molecular basis for this cytotoxicity is controversial, with a number of competing hypotheses in circulation. One suggestion is that the protective effect is related to the induction of expression of the DNA mismatch repair (MMR) proteins hMLH1, hMSH2, hMSH6 and hPMS2 in DNA MMR proficient cells. We report that treatment of the DNA MMR competent/p53 mutant colorectal cancer cell line SW480 with 1 mM aspirin for 48 h caused changes in mRNA expression of several key genes involved in DNA damage signalling pathways, including a significant down-regulation in transcription of the genes ATR, BRCA1 and MAPK12. Increases in the transcription of XRCC3 and GADD45alpha genes are also reported. Regulation of these genes could potentially have profound effects on colorectal cancer cells and may play a role in the observed chemo-protective effect of aspirin in vivo. Although a correlation was not seen between transcript and protein levels of ATR, BRCA1 and GADD45alpha, an increase in XRCC3 encoded protein expression upon aspirin treatment in SW480 cells was observed by immunoblotting, immunofluorescence and immunohistochemical analysis. This is the first report of XRCC3 gene transcription and encoded protein expression being susceptible to exposure to the non-steroidal anti-inflammatory drug, aspirin. Furthermore, this study indicates that alterations in gene transcription seen in microarray studies must be verified at the protein level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514442     DOI: 10.3892/or_00000826

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Do Platelets Inhibit the Effect of Aspirin on Cancer Cells?

Authors:  Neha Mehta; Sasikala Muthusamy; Alka Bhatia
Journal:  Cancer Microenviron       Date:  2015-07-04

Review 2.  Unboxing the molecular modalities of mutagens in cancer.

Authors:  Smita Kumari; Sudhanshu Sharma; Dia Advani; Akanksha Khosla; Pravir Kumar; Rashmi K Ambasta
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-05       Impact factor: 5.190

3.  Proteome-wide prediction of targets for aspirin: new insight into the molecular mechanism of aspirin.

Authors:  Shao-Xing Dai; Wen-Xing Li; Gong-Hua Li; Jing-Fei Huang
Journal:  PeerJ       Date:  2016-03-10       Impact factor: 2.984

Review 4.  Genome-Protecting Compounds as Potential Geroprotectors.

Authors:  Ekaterina Proshkina; Mikhail Shaposhnikov; Alexey Moskalev
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

Review 5.  Advances in antitumor effects of NSAIDs.

Authors:  Zhen Zhang; Fulin Chen; Lijun Shang
Journal:  Cancer Manag Res       Date:  2018-10-15       Impact factor: 3.989

6.  Aspirin impairs acetyl-coenzyme A metabolism in redox-compromised yeast cells.

Authors:  Gianluca Farrugia; Maria Azzopardi; Christian Saliba; Godfrey Grech; Angelina S Gross; Jelena Pistolic; Vladimir Benes; Neville Vassallo; Joseph Borg; Frank Madeo; Tobias Eisenberg; Rena Balzan
Journal:  Sci Rep       Date:  2019-04-16       Impact factor: 4.379

7.  The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort.

Authors:  Jin Ho Choi; Sang Hyub Lee; Gunn Huh; Jung Won Chun; Min Su You; Woo Hyun Paik; Ji Kon Ryu; Yong-Tae Kim
Journal:  Cancer Med       Date:  2019-10-21       Impact factor: 4.452

8.  Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention.

Authors:  Ranjini Sankaranarayanan; Chaitanya K Valiveti; Rakesh Dachineni; D Ramesh Kumar; Tana Lick; G Jayarama Bhat
Journal:  Mol Med Rep       Date:  2019-11-18       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.